Implantica AG (IMP-A-SDB.ST)
SEK 27.0
(0.56%)
SEK 27.0
(0.56%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -21.84 Million EUR | -18.39% |
| 2022 | -18.44 Million EUR | -40.38% |
| 2021 | -13.14 Million EUR | -23.49% |
| 2020 | -10.64 Million EUR | -132.84% |
| 2019 | -4.57 Million EUR | 10.53% |
| 2018 | -5.1 Million EUR | -31.77% |
| 2017 | -3.87 Million EUR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -5.86 Million EUR | 17.19% |
| 2024 Q1 | -7.08 Million EUR | -2.09% |
| 2023 Q1 | -4.87 Million EUR | 4.66% |
| 2023 FY | -21.84 Million EUR | -18.39% |
| 2023 Q4 | -6.94 Million EUR | -20.69% |
| 2023 Q3 | -5.75 Million EUR | -34.52% |
| 2023 Q2 | -4.27 Million EUR | 12.2% |
| 2022 Q4 | -5.1 Million EUR | -11.5% |
| 2022 Q3 | -4.58 Million EUR | -5.38% |
| 2022 Q2 | -4.34 Million EUR | 1.45% |
| 2022 FY | -18.44 Million EUR | -40.38% |
| 2022 Q1 | -4.41 Million EUR | -10.55% |
| 2021 Q3 | -3.9 Million EUR | -31.54% |
| 2021 Q2 | -2.96 Million EUR | -30.23% |
| 2021 Q1 | -2.27 Million EUR | 31.97% |
| 2021 Q4 | -3.99 Million EUR | -2.2% |
| 2021 FY | -13.14 Million EUR | -23.49% |
| 2020 FY | -10.64 Million EUR | -132.84% |
| 2020 Q2 | -1.1 Million EUR | 21.05% |
| 2020 Q4 | -3.35 Million EUR | 30.06% |
| 2020 Q3 | -4.79 Million EUR | -334.27% |
| 2020 Q1 | -1.39 Million EUR | -29.35% |
| 2019 Q3 | -748 Thousand EUR | 0.0% |
| 2019 Q4 | -1.08 Million EUR | -44.39% |
| 2019 FY | -4.57 Million EUR | 10.53% |
| 2018 FY | -5.1 Million EUR | -31.77% |
| 2017 FY | -3.87 Million EUR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Acarix AB (publ) | -77.55 Million SEK | 71.839% |
| ADDvise Group AB (publ) | 300.6 Million SEK | 107.265% |
| ADDvise Group AB (publ) | 300.6 Million SEK | 107.265% |
| Arcoma AB | 4.66 Million SEK | 568.67% |
| Bactiguard Holding AB (publ) | -131.93 Million SEK | 83.446% |
| BICO Group AB (publ) | -618.3 Million SEK | 96.468% |
| Boule Diagnostics AB (publ) | 39.27 Million SEK | 155.615% |
| CellaVision AB (publ) | 167.05 Million SEK | 113.074% |
| Clinical Laserthermia Systems AB (publ) | -65.93 Million SEK | 66.875% |
| Chordate Medical Holding AB (publ) | -29.57 Million SEK | 26.145% |
| C-Rad AB (publ) | 44.24 Million SEK | 149.363% |
| Duearity AB (publ) | -25.76 Million SEK | 15.227% |
| Dignitana AB (publ) | -15.02 Million SEK | -45.348% |
| Episurf Medical AB (publ) | -94.8 Million SEK | 76.962% |
| Getinge AB (publ) | 3.81 Billion SEK | 100.573% |
| Scandinavian Real Heart AB (Publ) | -68.44 Million SEK | 68.092% |
| Iconovo AB (publ) | -45.77 Million SEK | 52.29% |
| Integrum AB (publ) | 6.51 Million SEK | 435.363% |
| Luxbright AB (publ) | -25.8 Million SEK | 15.363% |
| Mentice AB (publ) | -679 Thousand SEK | -3116.495% |
| OssDsign AB (publ) | -91.95 Million SEK | 76.25% |
| Paxman AB (publ) | 12.61 Million SEK | 273.072% |
| Promimic AB (publ) | -9.11 Million SEK | -139.526% |
| Qlife Holding AB (publ) | -168.69 Million SEK | 87.054% |
| SciBase Holding AB (publ) | -53.93 Million SEK | 59.51% |
| ScandiDos AB (publ) | -13.48 Million SEK | -61.982% |
| Sectra AB (publ) | 518.49 Million SEK | 104.212% |
| Sedana Medical AB (publ) | -65.54 Million SEK | 66.68% |
| Senzime AB (publ) | -133.74 Million SEK | 83.67% |
| SpectraCure AB (publ) | -21.35 Million SEK | -2.29% |
| Stille AB | 44.95 Million SEK | 148.585% |
| Vitrolife AB (publ) | -3.58 Billion SEK | 99.391% |
| Xvivo Perfusion AB (publ) | 38.5 Million SEK | 156.718% |